Success Metrics

Clinical Success Rate
90.0%

Based on 9 completed trials

Completion Rate
90%(9/10)
Active Trials
6(30%)
Results Posted
44%(4 trials)
Terminated
1(5%)

Phase Distribution

Ph phase_2
11
55%
Ph phase_1
4
20%
Ph phase_3
2
10%
Ph not_applicable
1
5%
Ph phase_4
1
5%

Phase Distribution

4

Early Stage

11

Mid Stage

3

Late Stage

Phase Distribution19 total trials
Phase 1Safety & dosage
4(21.1%)
Phase 2Efficacy & side effects
11(57.9%)
Phase 3Large-scale testing
2(10.5%)
Phase 4Post-market surveillance
1(5.3%)
N/ANon-phased studies
1(5.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

6

trials recruiting

Total Trials

20

all time

Status Distribution
Active(6)
Completed(9)
Terminated(1)
Other(4)

Detailed Status

Completed9
Recruiting5
unknown4
Terminated1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
20
Active
6
Success Rate
90.0%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (21.1%)
Phase 211 (57.9%)
Phase 32 (10.5%)
Phase 41 (5.3%)
N/A1 (5.3%)

Trials by Status

recruiting525%
terminated15%
unknown420%
active_not_recruiting15%
completed945%

Recent Activity

6 active trials
Showing 5 of 20
active_not_recruitingphase_1

Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia

NCT05357482
completedphase_1

Haplo Peripheral Blood Sct In GVHD Prevention

NCT04473911
completedphase_2

UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

NCT02722668
terminated

FlowMet-R Blood Flow Measurement for the Diagnosis of Peripheral Artery Disease and Critical Limb Ischemia

NCT04120610
recruitingphase_2

A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL

NCT06564493
View all 20 trials

Clinical Trials (20)

Showing 20 of 20 trials
NCT05357482Phase 1

Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia

Active Not Recruiting
NCT04473911Phase 1

Haplo Peripheral Blood Sct In GVHD Prevention

Completed
NCT02722668Phase 2

UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

Completed
NCT04120610

FlowMet-R Blood Flow Measurement for the Diagnosis of Peripheral Artery Disease and Critical Limb Ischemia

Terminated
NCT06564493Phase 2

A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL

Recruiting
NCT06559345Phase 2

A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL

Recruiting
NCT06564545Phase 2

A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL

Recruiting
NCT06557161Phase 2

A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL

Recruiting
NCT01949129Phase 2

Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

Recruiting
NCT02661035Phase 2

Allo HSCT Using RIC for Hematological Diseases

Completed
NCT02224872Phase 2

Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia

Completed
NCT02120157Phase 2

Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies

Completed
NCT03885947Phase 1

VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies

Completed
NCT01370226Not Applicable

Health Explorer - Optimizing Alcohol Brief Interventions

Completed
NCT01873807Phase 4

HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL

Unknown
NCT01423500Phase 3

ALL-SCT BFM International- HSCT in Children and Adolescents With ALL

Unknown
NCT01423747Phase 3

Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia

Unknown
NCT00472329Phase 2

Fludarabine and 400 CGY Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor Hematopoietic Stem Cell Transplants Who Have Rejected Their First Allogeneic Stem Cell Transplant

Unknown
NCT00005622Phase 2

Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

Completed
NCT00270881Phase 1

Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies

Completed

All 20 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
20